Abstracts Archive - Page 1720 of 2607 - ACR Meeting Abstracts

Abstract Number: 1813 • 2016 ACR/ARHP Annual Meeting
Prevalence and Incidence of Systemic Lupus Erythematosus in Tucuman -Argentina
Luciana Gonzalez Lucero¹, Raul Sueldo², Alberto Ives Torres³, Alexia Cristofari³, Ana Lucía Barbaglia³, Ana Olea³, Ana Quinteros⁴, Gladys Seleme³, Francisco Colombres³, Dora Lia Vásquez³, Gustavo Arquez³, Gustavo Alberto Carrizo³, Hector Lazaro³, Maria Josefina Molina³, Laura Juarez³, Maria Constanza Bertolaccini⁵, Maria Olga Leal⁶, María Silvia Yacuzzi², Mariana Espindola Echazu³, Norma Robles De Garrone³, Rodolfo Orlando Dip³, Olga Romano³, Oscar Pera³, Silvia Paz³, Veronica Bellomio⁷, Maximiliano Machado Escobar², Silvia Rengel⁸, Liliana Galindo⁷, Mirta Santana² and Eleonora Lucero², ¹Rheumatology Unit, Hospital Padilla, Tucumán, Tucumán, Argentina, ²Hospital Angel Cruz Padilla, Tucumán, Argentina, ³Sociedad de Reumatología de Tucumán, tucuman, Argentina, ⁴Centro Integral Reumatológico, Tucuman, Argentina, ⁵Rheumatology, Hospital Angel Cruz Padilla, Tucumán, Argentina, ⁶Centro Integral De Reumatologia, Tucumán, Argentina, ⁷Hospital Ángel Cruz Padilla, Tucuman, Argentina, ⁸Hospital Centro de Salud, Tucuman, Argentina
Background/Purpose: Systemic Lupus Erythematosus (SLE) is the paradigm of the autoimmune diseases that primarily affects women in a ratio of 9: 1. In England and…
Abstract Number: 1814 • 2016 ACR/ARHP Annual Meeting
Epidemiology and Microbiology of Pneumonia in Systemic Lupus Erythematosus (SLE)
Gabriela García-Guevara¹, Ricardo Ríos-Corzo², Hilda Fragoso-Loyo³, Juan Jakez-Ocampo⁴, John Hernandez-Flores², Mariana Lopez-Lopez⁵, Eduardo Carrillo-Maravilla⁶, Jose Sifuentes-Osornio² and Yemil Atisha-Fregoso⁷, ¹Internal Medicine, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, Mexico, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁶Medicina Interna, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ⁷Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Background/Purpose: Pneumonia, remains as a main cause of mortality in patients with SLE. There are not specific guidelines for the empiric treatment in these patients.…
Abstract Number: 1815 • 2016 ACR/ARHP Annual Meeting
Frequency and Predictors of Attaining the Lupus Low Disease Activity State (LLDAS) in a Multinational SLE Cohort from the Asia Pacific
Vera Golder¹, Rangi Kandane-Rathnayake², Alberta Y. Hoi³, Molla Huq⁴, Worawit Louthrenoo⁵, Yuan An⁶, Zhanguo Li⁶, Shue Fen Luo⁷, Sargunan Sockalingam⁸, Chak Sing Lau⁹, Alfred Lee¹⁰, Mo Yin Mok¹⁰, Aisha Lateef¹¹, Kate Franklyn³, Susan Morton¹², Sandra V. Navarra¹³, Leonid Zamora¹³, Yeong-Jian Wu⁷, Laniyati Hamijoyo¹⁴, Madelynn Chan¹⁵, Sean O'Neill¹⁶, Fiona Goldblatt¹⁷, Eric F Morand³, Mandana Nikpour¹⁸ and Asia Pacific Lupus Collaboration, ¹Southern Clinical School, Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ²Rheumatology, Monash University, Melbourne, Australia, ³Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁴Department of Medicine (Rheumatology), Melbourne University, Melbourne, Australia, ⁵Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁶Peking University People's Hospital, Beijing, China, ⁷Chang Gung University, Taoyuan County, Taiwan, ⁸University of Malaya, Kuala Lumpur, Malaysia, ⁹Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ¹⁰Queen Mary Hospital, Hong Kong, Hong Kong, ¹¹Medicine/Rheumatology, National University Health System, Singapore, Singapore, ¹²Monash Health, Melbourne, Australia, ¹³Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ¹⁴University of Padjadjaran, Bandung, Indonesia, ¹⁵Tan Tock Seng Hospital, Singapore, Singapore, ¹⁶University of New South Wales, Sydney, Australia, ¹⁷Royal Adelaide Hospital, Adelaide, Australia, ¹⁸Melbourne University, Melbourne, Australia
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic heterogeneous disease with considerable burden from disease activity and damage. A novel clinical treatment target in the…
Abstract Number: 1816 • 2016 ACR/ARHP Annual Meeting
SLE and Uctd in the Rheumatology Informatics System for Effectiveness (RISE) Registry
Julia F Simard¹, Jim Oates², Jinoos Yazdany³, Nick Bansback⁴, Deborah Collier⁵, Karen Law⁶, Katherine Liao⁷, Kaleb Michaud⁸, Esi Morgan⁹, Catalina Orozco¹⁰, Andreas Reimold¹¹, Rachel Myslinski¹², Tracy Johansson¹³, Salahuddin Kazi¹⁴ and Megan E. B. Clowse¹⁵, ¹Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ²Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Population and Public Health, The University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Internal Medicine, Emory University School of Medicine, Atlanta, GA, ⁷Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ⁸University of Nebraska Medical Center, Omaha, NE, ⁹Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Rheumatology Associates, Dallas, TX, ¹¹Hospital of Southern Norway, Kristiansand, Norway, ¹²Governance & Ethics Specialist, Amer College of Rheumatology, Atlanta, GA, ¹³Practice, Advocacy & Quality, American College of Rheumatology, Atlanta, GA, ¹⁴Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹⁵Rheumatology, Duke University School of Medicine, Durham, NC
Background/Purpose: The ACR-sponsored RISE (Rheumatology Informatics System for Effectiveness) Registry is an electronic health record (EHR)-based national database of rheumatology clinical visits. De-identified patient data…
Abstract Number: 1817 • 2016 ACR/ARHP Annual Meeting
A Longitudinal Analysis of Change in Lupus Disease Activity Pattern in Hopkins Lupus Cohort Using a Multistate Markov Model Approach
Wei Fu¹ and Michelle Petri², ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-systemic inflammatory disease with extreme variability of its activity over time. We have described three main patterns: long…
Abstract Number: 1818 • 2016 ACR/ARHP Annual Meeting
Predictors for Mortality in Hospitalized Patients with Systemic Lupus Erythematosus from 1999 to 2009: A Follow-up Multicenter Study in China
Xuebing Feng¹, Wenyou Pan², Lin Liu³, Min Wu⁴, Lingyun Sun⁵ and Jiangsu Lupus Collaborative Group, ¹Department of Rheumatology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Huaian First People’s Hospital, Huaian, China, ³Xuzhou No. 4 People’s Hospital, Xuzhou, China, ⁴the 3rd Affiliated Hospital of Suzhou University, Changzhou, China, ⁵the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: To find out prognostic factors predicting the outcome of Chinese patients with systemic lupus erythematosus (SLE) at the time of their first admission. Methods: A…
Abstract Number: 1819 • 2016 ACR/ARHP Annual Meeting
Myocarditis in Systemic Lupus Erythematosus
Alexandra Perel-Winkler¹, Sabahat Bokhari², Anca D. Askanase³ and Laura Geraldino-Pardilla⁴, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Cardiology, Columbia University College of Physicians & Surgeons, NY, NY, ³Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁴Columbia University College of Physicians & Surgeons, new york, NY
Background/Purpose : Cardiovascular disease (CVD) is a leading cause of death in patients with SLE. Lupus patients have a 2-3 fold increased risk of heart…
Abstract Number: 1820 • 2016 ACR/ARHP Annual Meeting
Dectin-1 on Monocytic Cells Mediates Aberrant Innate and Adaptive Immune Responses in Patients with Systemic Lupus Erythematosus
Mo Yin Mok, Ian Lam, Daniel Luk, Yi Lo and Wai Kin Chan, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Dectin-1 is a c-type lectin like receptor that signals via syk and is involved in anti-fungal immunity. Dectin-1 was found to trigger experimental inflammatory…
Abstract Number: 1821 • 2016 ACR/ARHP Annual Meeting
Demethylated CD4+CD28+KIR+CD11ahi T Cells Are Characterized By a Pro-Inflammatory Transcriptome and Interact with Genetic Risk to Predict Disease Activity in Lupus
Paul Renauer¹, Patrick Coit¹, Faith Strickland², Elizabeth Gensterblum¹, Mikhail Ognenovski¹, Bruce Richardson³ and Amr Sawalha⁴, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Rheumatology, University of Michigan, Ann Arbor, MI, ³Rheumatology, University of Michigan and the Ann Arbor VA, Ann Arbor, MI, ⁴Internal Medicine-Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: T cell DNA methylation defects play an important role in the pathogenesis of systemic lupus erythematosus. A CD4+CD28+ T cell subset characterized by overexpression…
Abstract Number: 1822 • 2016 ACR/ARHP Annual Meeting
CD4+ T Cell Lymphopenia Is Associated with Deficient Ubiquitination of the Cell Cycle Inhibibitor p27kip1 By the E3 Ligase Casitas B-Lineage Lymphoma-b in Patients with Systemic Lupus Erythematosus
Diana Gómez-Martín, Jorge Romo-Tena, Javier Merayo-Chalico and Jorge Alcocer-Varela, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Lymphopenia has been associated with the development of autoimmune diseases. Particularly, in patients with Systemic Lupus Erythematosus (SLE) is a common clinical feature. However,…
Abstract Number: 1823 • 2016 ACR/ARHP Annual Meeting
African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in CD4+ T Cell and Monocyte Pathways
Samantha Slight-Webb¹, Rufei Lu², Krista M. Bean¹, Holden T. Maecker³, Paul J. Utz⁴, Joel M. Guthridge⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder with both genetic and environmental contributions to disease etiology. Patients with different ancestral backgrounds have different…
Abstract Number: 1824 • 2016 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Use Associates with Unique Biologic Changes in B Cell and T Regulatory Cell Pathways in SLE Patients
Samantha Slight-Webb¹, Rufei Lu², Krista M. Bean¹, Holden T. Maecker³, Paul J. Utz⁴, Joel M. Guthridge⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: The management of systemic lupus erythematosus (SLE) is complicated by a heterogeneous clinical presentation. Currently, mycophenolate mofetil (MMF) is a commonly used medication to…
Abstract Number: 1825 • 2016 ACR/ARHP Annual Meeting
the Non-Coding Genome and the Genetics of Systemic Lupus
Joyce Hui-Yuen¹, Lisha Zhu², Lai Ping Wong³, Kaiyu Jiang⁴, Yanmin Chen⁴, Tao Liu⁵ and James Jarvis⁶, ¹North Shore-Long Island Jewish Health System, Lake Success, NY, ²Biochemistry, University at Buffalo, Buffalo, NY, ³Pediatrics, University at Buffalo, Buffalo, NY, ⁴Pediatrics, The University at Buffalo, Buffalo, NY, ⁵Department of Biochemistry, University at Buffalo, Buffalo, NY, ⁶Pediatrics, SUNY Buffalo School of Medicine, Buffalo, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system, complex disease believed to be triggered by gene-environment interactions. While we have made considerable progress in investigation…
Abstract Number: 1826 • 2016 ACR/ARHP Annual Meeting
STAT3 Phosphorylation Mediates the Stimulatory Effects of Interferon Alpha on B Cell Differentiation and Activation in SLE
Julie Ducreux¹, Floor Aleva², Aurelie Degroof³, Alina Ferster⁴, Andre van der Ven², Frank van de Veerdonk², Frédéric A. Houssiau¹ and Bernard R. Lauwerys¹, ¹Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ²Department of General Internal Medicine, Radboud University, Nijmegen, Netherlands, ³Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ⁴Service d'Onco-Hématologie, Hôpital Reine Fabiola, Brussels, Belgium
Background/Purpose: In our previous work, we reported a link between interferon alpha inhibition and decreased expression of B cell activation genes in ex vivo whole…
Abstract Number: 1827 • 2016 ACR/ARHP Annual Meeting
Type I IFN Signature Low and High SLE Subjects with Moderate to Severe Disease Activity Have Distinct Gene Expression Signatures of Immunologic Pathways and Cell Types
Hao Liu¹, Brandon Higgs², William Rees³, Chris Morehouse⁴, Katie Streicher⁵, P Brohawn², G. Illei⁶ and K Ranade², ¹Translational Medicine, Medimmune, LLC, Gaithers, MD, ²MedImmune, Gaithersburg, MD, ³Translational Medicine, Medimmune, LLC, Gaithersburg, MD, ⁴Medimmune, LLC, Gaithers, MD, ⁵Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁶Medimmune, Gaithersburg, MD
Background/Purpose: Type I interferon (IFN) has been implicated in SLE pathogenesis, and the majority of subjects with SLE have elevated expression of type I IFN-inducible…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].